SCHEMBL11214

SCHEMBL11214

COc1cc(-c2n[nH]c3ncnc(N)c23)ccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.48
SRC P12931 16/20 0.46
ABL1 P00519 15/20 0.46
PIK3CD O00329 14/20 0.46
EGFR P00533 14/20 0.46
HCK P08631 14/20 0.46
PIK3CA P42336 14/20 0.46
PIK3CB P42338 14/20 0.46
MTOR P42345 14/20 0.46
PIK3CG P48736 14/20 0.46
EPHB4 P54760 14/20 0.46
PRKDC P78527 14/20 0.46
KDR P35968 13/20 0.46
PI4KB Q9UBF8 13/20 0.46
KMO O15229 1/20 0.43
LIMK1 P53667 1/20 0.41
RET P07949 1/20 0.40
KIF5B P33176 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19414295 0.90 SRC (0.47) SRCABL1PIK3CDEGFRHCK
SCHEMBL149180 0.88 PIK3CD (0.55) SRCABL1PIK3CDEGFRHCK
SCHEMBL10811 0.85 SRC (0.57) SRCABL1PIK3CDEGFRHCK
SCHEMBL16665685 0.83 PIK3CD (0.67) SRCABL1PIK3CDEGFRHCK
SCHEMBL11306 0.82 SRC (0.47) SRCABL1PIK3CDEGFRHCK
SCHEMBL21467104 0.81 PIK3CD (0.54) SRCABL1PIK3CDEGFRHCK
SCHEMBL20093481 0.80 KMO (0.46) SRCABL1PIK3CDEGFRHCK
SCHEMBL17365228 0.79 PDGFRB (0.46) SRCABL1PIK3CDEGFRHCK
SCHEMBL149528 0.79 KDR (0.52) DYRK1ASRCABL1PIK3CDEGFR
SCHEMBL19414290 0.79 SRC (0.57) SRCABL1PIK3CDEGFRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP disclosed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 EP disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 US disclosed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 EP disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 DYRK1A 1186/4885SRC 202/4885ABL1 329/4885
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB DYRK1A 1535/4885SRC 314/4885ABL1 465/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB DYRK1A 1535/4885SRC 314/4885ABL1 465/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB DYRK1A 1535/4885SRC 314/4885ABL1 465/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB DYRK1A 1535/4885SRC 314/4885ABL1 465/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB DYRK1A 1535/4885SRC 314/4885ABL1 465/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A DYRK1A 618/4885SRC 110/4885ABL1 258/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB DYRK1A 1535/4885SRC 314/4885ABL1 465/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB DYRK1A 1535/4885SRC 314/4885ABL1 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.